Optimization of antitumor modulators of pre-mRNA splicing

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 10033-10044

  Lagisetti, Chandraiah ^a   Palacios, Gustavo ^a   Goronga, Tinopiwa ^a   Freeman, Burgess ^a   Caufield, William ^a   Webb, Thomas R ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BORTEZOMIB; CAMPTOTHECIN; DACTOLISIB; HARRINGTONINE; IMATINIB; MESSENGER RNA PRECURSOR; NATURAL PRODUCT; PACLITAXEL; PANOBINOSTAT; SILIBININ; SORAFENIB; SU 9516; SUDEMYCIN C1; SUDEMYCIN D1; SUDEMYCIN D6; SUDEMYCIN F1; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKHOLDERIA THAILANDENSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; RNA SPLICING; SPLICEOSOME; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

EID: 84891323481     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401370h     Document Type: Article

References (49)

1. Kramer, A. The structure and function of proteins involved in mammalian pre-mRNA splicing Annu. Rev. Biochem. 1996, 65, 367-409
2. Golas, M. M.; Sander, B.; Will, C. L.; Luhrmann, R.; Stark, H. Molecular architecture of the multiprotein splicing factor SF3b Science 2003, 300, 980-984
3. Staley, J. P.; Guthrie, C. Mechanical devices of the spliceosome: Motors, clocks, springs, and things Cell 1998, 92, 315-326
4. Germann, S.; Gratadou, L.; Dutertre, M.; Auboeuf, D. Splicing programs and cancer J. Nucleic Acids 2012, 2012, 269570-1-269570-9
5. Nakajima, H.; Hori, Y.; Terano, H.; Okuhara, M.; Manda, T.; Matsumoto, S.; Shimomura, K. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action J. Antibiot. 1996, 49, 1204-1211
6. Nakajima, H.; Sato, B.; Fujita, T.; Takase, S.; Terano, H.; Okuhara, M. New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities J. Antibiot. 1996, 49, 1196-1203
7. Nakajima, H.; Takase, S.; Terano, H.; Tanaka, H. New antitumor substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465 J. Antibiot. 1997, 50, 96-99
8. Mizui, Y.; Sakai, T.; Iwata, M.; Uenaka, T.; Okamoto, K.; Shimizu, H.; Yamori, T.; Yoshimatsu, K.; Asada, M. Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities J. Antibiot. 2004, 57, 188-196
9. Asai, N.; Kotake, Y.; Niijima, J.; Fukuda, Y.; Uehara, T.; Sakai, T. Stereochemistry of pladienolide B J. Antibiot. 2007, 60, 364-369
10. Kaida, D.; Motoyoshi, H.; Tashiro, E.; Nojima, T.; Hagiwara, M.; Ishigami, K.; Watanabe, H.; Kitahara, T.; Yoshida, T.; Nakajima, H.; Tani, T.; Horinouchi, S.; Yoshida, M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA Nat. Chem. Biol. 2007, 3, 576-583
11. Kotake, Y.; Sagane, K.; Owa, T.; Mimori-Kiyosue, Y.; Shimizu, H.; Uesugi, M.; Ishihama, Y.; Iwata, M.; Mizui, Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide Nat. Chem. Biol. 2007, 3, 570-575
12. Hasegawa, M.; Miura, T.; Kuzuya, K.; Inoue, A.; Won, K. S.; Horinouchi, S.; Yoshida, T.; Kunoh, T.; Koseki, K.; Mino, K.; Sasaki, R.; Yoshida, M.; Mizukami, T. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product ACS Chem. Biol. 2011, 6, 229-233
13. Liu, X.; Biswas, S.; Berg, M. G.; Antapli, C. M.; Xie, F.; Wang, Q.; Tang, M. C.; Tang, G. L.; Zhang, L.; Dreyfuss, G.; Cheng, Y. Q. Genomics-guided discovery of thailanstatins A, B, and C as pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43 J. Nat. Prod. 2013, 76, 685-693
14. Mandel, A. L.; Jones, B. D.; La Clair, J. J.; Burkart, M. D. A synthetic entry to pladienolide B and FD-895 Bioorg. Med. Chem. Lett. 2007, 17, 5159-5164
15. Villa, R.; Mandel, A. L.; Jones, B. D.; La Clair, J. J.; Burkart, M. D. Structure of FD-895 revealed through total synthesis Org. Lett. 2012, 14, 5396-5399
16. Sakai, Y.; Tsujita, T.; Akiyama, T.; Yoshida, T.; Mizukami, T.; Akinaga, S.; Horinouchi, S.; Yoshida, M. GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. II. The effects on cell cycle progression and gene expression J. Antibiot. 2002, 55, 863-872
17. Webb, T. R.; Joyner, A. S.; Potter, P. M. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer Drug Discovery Today 2013, 18, 43-49
18. Venables, J. P. Aberrant and alternative splicing in cancer Cancer Res. 2004, 64, 7647-7654
19. Kalnina, Z.; Zayakin, P.; Silina, K.; Line, A. Alterations of pre-mRNA splicing in cancer Genes, Chromosomes Cancer 2005, 42, 342-357
20. Bonnal, S.; Vigevani, L.; Valcarcel, J. The spliceosome as a target of novel antitumour drugs Nat. Rev. Drug Discovery 2012, 11, 847-859
21. Ogawa, S. Splicing factor mutations in myelodysplasia Int. J. Hematol. 2012, 96, 438-442
22. Damm, F.; Nguyen-Khac, F.; Fontenay, M.; Bernard, O. A. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies Leukemia 2012, 26, 2027-2031
23. Murati, A.; Brecqueville, M.; Devillier, R.; Mozziconacci, M. J.; Gelsi-Boyer, V.; Birnbaum, D. Myeloid malignancies: Mutations, models and management BMC Cancer 2012, 12, 304
24. Harbour, J. W.; Roberson, E. D.; Anbunathan, H.; Onken, M. D.; Worley, L. A.; Bowcock, A. M. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma Nat. Genet. 2013, 45, 133-135
25. Hubert, C. G.; Bradley, R. K.; Ding, Y.; Toledo, C. M.; Herman, J.; Skutt-Kakaria, K.; Girard, E. J.; Davison, J.; Berndt, J.; Corrin, P.; Hardcastle, J.; Basom, R.; Delrow, J. J.; Webb, T.; Pollard, S. M.; Lee, J.; Olson, J. M.; Paddison, P. J. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A Genes Dev. 2013, 27, 1032-1045
26. Gao, Y.; Koide, K. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells ACS Chem. Biol. 2013, 8, 895-900
27. Osman, S.; Albert, B. J.; Wang, Y.; Li, M.; Czaicki, N. L.; Koide, K. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464 Chem.-Eur. J. 2011, 17, 895-904
28. Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. Convergent assembly of chiral components prepared by asymmetric catalysis J. Am. Chem. Soc. 2000, 122, 10482-10483
29. Horigome, M.; Motoyoshi, H.; Watanabe, H.; Kitahara, T. A synthesis of FR901464 Tetrahedron Lett. 2001, 42, 8207-8210
30. Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. FR901464: Total synthesis, proof of structure, and evaluation of synthetic analogues J. Am. Chem. Soc. 2001, 123, 9974-9983
31. Albert, B. J.; Sivaramakrishnan, A.; Naka, T.; Koide, K. Total synthesis of FR901464, an antitumor agent that regulates the transcription of oncogenes and tumor suppressor genes J. Am. Chem. Soc. 2006, 128, 2792-2793
32. Albert, B. J.; Sivaramakrishnan, A.; Naka, T.; Czaicki, N. L.; Koide, K. Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue J. Am. Chem. Soc. 2007, 129, 2648-2659
33. Lagisetti, C.; Pourpak, A.; Jiang, Q.; Cui, X.; Goronga, T.; Morris, S. W.; Webb, T. R. Antitumor compounds based on a natural product consensus pharmacophore J. Med. Chem. 2008, 51, 6220-6224
34. Lagisetti, C.; Pourpak, A.; Goronga, T.; Jiang, Q.; Cui, X.; Hyle, J.; Lahti, J. M.; Morris, S. W.; Webb, T. R. Synthetic mRNA splicing modulator compounds with in vivo antitumor activity J. Med. Chem. 2009, 52, 6979-6990
35. Fan, L.; Lagisetti, C.; Edwards, C. C.; Webb, T. R.; Potter, P. M. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing ACS Chem. Biol. 2011, 6, 582-589
36. Gundluru, M. K.; Pourpak, A.; Cui, X.; Morris, S. W.; Webb, T. R. Design, synthesis and initial biological evaluation of a novel pladienolide analog scaffold MedChemCommun 2011, 2, 904-908
37. Jennings, L.; Murphy, G. M. Predicting outcome in melanoma: where are we now? Br. J. Dermatol. 2009, 161, 496-503
38. Smith, A. B., 3rd.; Dong, S.; Brenneman, J. B.; Fox, R. J. Total synthesis of (+)-sorangicin A J. Am. Chem. Soc. 2009, 131, 12109-12111
39. Lawrence, N. J.; Drew, M. D.; Bushell, S. M. Polymethylhydrosiloxane: A versatile reducing agent for organic synthesis J. Chem. Soc., Perkin Trans. 1 1999, 0, 3381-3391
40. Goddard-Borger, E. D.; Stick, R. V. An efficient, inexpensive, and shelf-stable diazotransfer reagent: Imidazole-1-sulfonyl azide hydrochloride Org. Lett. 2007, 9, 3797-3800
41. Ye, H.; Liu, R.; Li, D.; Liu, Y.; Yuan, H.; Guo, W.; Zhou, L.; Cao, X.; Tian, H.; Shen, J.; Wang, P. G. A safe and facile route to imidazole-1-sulfonyl azide as a diazotransfer reagent Org. Lett. 2012, 15, 18-21
42. Lehar, J.; Krueger, A. S.; Avery, W.; Heilbut, A. M.; Johansen, L. M.; Price, E. R.; Rickles, R. J.; Short, G. F., 3rd.; Staunton, J. E.; Jin, X.; Lee, M. S.; Zimmermann, G. R.; Borisy, A. A. Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat. Biotechnol. 2009, 27, 659-666
43. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 2008, 7, 1851-1863
44. LoPiccolo, J.; Blumenthal, G. M.; Bernstein, W. B.; Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations Drug Resist. Updates 2008, 11, 32-50
45. Liu, J. Y.; Park, S. H.; Morisseau, C.; Hwang, S. H.; Hammock, B. D.; Weiss, R. H. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo Mol. Cancer Ther. 2009, 8, 2193-2203
46. Decker, M.; Arand, M.; Cronin, A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling Arch. Toxicol. 2009, 83, 297-318
47. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
48. Laizure, S. C.; Herring, V.; Hu, Z.; Witbrodt, K.; Parker, R. B. The role of human carboxylesterases in drug metabolism: Have we overlooked their importance? Pharmacotherapy 2013, 33, 210-222
49. Fischer, N.; Goddard-Borger, E. D.; Greiner, R.; Klapötke, T. M.; Skelton, B. W.; Stierstorfer, J. Sensitivities of some imidazole-1-sulfonyl azide salts J. Org. Chem. 2012, 77, 1760-1764